Juno Therapeutics, Inc. (JUNO) Shares Sold by D.A. Davidson & CO.
D.A. Davidson & CO. trimmed its position in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 3.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 210,373 shares of the biopharmaceutical company’s stock after selling 8,645 shares during the quarter. D.A. Davidson & CO. owned 0.18% of Juno Therapeutics worth $9,436,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Advisor Group Inc. boosted its holdings in Juno Therapeutics by 141.1% during the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,439 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares during the period. Pacad Investment Ltd. purchased a new position in Juno Therapeutics during the 2nd quarter valued at about $105,000. QS Investors LLC purchased a new position in Juno Therapeutics during the 2nd quarter valued at about $135,000. Finally, Wellington Shields & Co. LLC purchased a new position in Juno Therapeutics during the 3rd quarter valued at about $202,000. Institutional investors own 66.96% of the company’s stock.
A number of equities analysts recently commented on JUNO shares. Wedbush upgraded Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 target price for the company in a report on Tuesday, August 29th. Wells Fargo & Company restated an “outperform” rating and set a $54.00 target price (up from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Raymond James Financial, Inc. lifted their price objective on Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Standpoint Research reiterated a “reduce” rating on shares of Juno Therapeutics in a research note on Thursday, August 31st. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $44.00 price objective on shares of Juno Therapeutics in a research note on Friday, October 6th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $44.20.
Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) traded down $0.29 during midday trading on Wednesday, hitting $58.77. The stock had a trading volume of 1,668,200 shares, compared to its average volume of 2,053,920. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics, Inc. has a 1-year low of $17.52 and a 1-year high of $61.59.
Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the company earned ($0.57) EPS. The business’s quarterly revenue was up 115.4% on a year-over-year basis. equities analysts forecast that Juno Therapeutics, Inc. will post -4.02 EPS for the current year.
In other news, insider Sunil Agarwal sold 7,285 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Robert Azelby sold 12,869 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $39.95, for a total value of $514,116.55. Following the sale, the executive vice president now directly owns 50,289 shares in the company, valued at approximately $2,009,045.55. The disclosure for this sale can be found here. Insiders have sold a total of 79,670 shares of company stock worth $3,553,777 in the last three months. Corporate insiders own 15.26% of the company’s stock.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.